Manuscript Proposals & Publications

• Early-childhood body mass index and its association with the COVID 19 pandemic, containment measures and islet autoimmunity in children with increased risk for type 1 diabetes
  Hummel S, Ziegler AG et al. Diabetologia 2024 Apr;67(4):670-678.
• Infection episodes and islet autoantibodies in children at increased risk for type 1 diabetes before and during the COVID-19 pandemic
  Zeller I, Ziegler AG et al. Infection 2024 Dec;52(6):2465-2473.
• Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes
  Hendriks E, Marcovecchio L et al. Diabetes Metab Res Rev. 2024 Feb;40(2):e3777.
• Vitamin D insufficiency in infants with increased risk of developing type 1 diabetes: a secondary analysis of the POInT Study 
  Jacobs A, Warnants M et al. BMJ Paediatr Open. 2024 Jan 12;8(1):e002212.
• Maternal type 1 diabetes and alterations in blood DNA methylation of their offspring
  Hummel S, Ott R, Ziegler AG (submitted)
• Genetics of circulating proteins in newborn babies identifies drivers of type 1 diabetes risk and therapeutic targets
  Yiu-Lin Yu N, Tutino M et al. (in revision)

• SARS-CoV-2 infection is associated with the development of islet autoimmunity in early childhood
  Bonifacio E, Lugar M et al. JAMA 2023 Sep 26;330(12):1151-1160.

• The emotional well-being of parents with children at genetic risk for type 1 diabetes before and during participation in the POInT-study
  Houben J, Janssens M et al. Pediatr Diabetes. 2022 Dec;23(8):1707-1716.
• Elevations in blood glucose before and after the appearance of islet autoantibodies in children
  Warncke K, Weiss A et al. J Clin Invest. 2022 Oct 17;132(20):e162123.

• Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol
  Ziegler AG, Arnolds S et al. BMJ Open. 2021 Nov 9;11(11):e052449.

• Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.
  Ziegler AG, Achenbach P et al. BMJ Open. 2019 Jun 28;9(6):e028578.

POInT Manuscript Proposals:

• Longitudinal comparison of islet and gut autoantibody detection in infants at high genetic risk for type 1 diabetes by the gold standard radiobinding assays and luciferase immunoprecipitation assays
  K. Gillespie (University Bristol, UK), A.G. Ziegler et al
• Investigation of the relationship between HLA/ major autoimmune-variants and microbiome in the pathophysiology of Type 1 Diabetes
  Y. Luo, E. Ng, J. Todd et al
• Neutrophil and whole blood counts in children with increased risk for type 1 diabetes
  G. Gemulla, A. Hommel, E. Bonifacio et al
• Early metabolic markers in relation to growth and development of islet autoimmunity in POInT
  H. Elding-Larsson et al
• Parental anxiety before and after their child develops islet autoantibodies
  J. Melin et al
• Analysis plan: Capacity of peripheral blood DNA methylation to predict progression from stage 1 to stage 3 type 1 diabetes in the Fr1da study
  C. Relton (University Bristol, UK), A.G. Ziegler et al
• Natural history of autoimmunity in children with increased risk of type 1 diabetes: from birth to insulin-dependency
  O. Kordonouri et al
• Tissue transglutaminase and thyroid peroxidase autoimmunity in children with an elevated genetic risk for type 1 diabetes.
  M. Sporreiter, E. Bonifacio, A.G. Ziegler
• Single cell multiome signatures to decipher the maternal T1D induced protective mechanisms against islet autoimmunity development (for POInT PBMC samples in Munich and Dresden)
  E. Bonifacio, A.G. Ziegler, F. Büttner (University of Frankfurt / DKFZ)
• DNA methylation status in children infected by SARS-CoV-2
  E. Bonifacio, R. Ott, T. Singh
• European newborn screening for an increased risk of type 1 diabetes
  C. Winkler et al
• Early metabolic markers and growth in relation to thyroid autoimmunity
  H. Elding-Larsson et all

SINT1A Manuscript Proposals:

• HbA1c levels in young children with a genetic risk for type 1 diabetes (0-5 years old)
  K. Casteels, A. Jacobs et al

POInT & SINT1A Manuscript Proposals:

• Characteristics of children enrolled in GPPAD primary prevention trials POInT and SINT1A
  S. Hummel, A. G. Ziegler et al
• Starting insulin in children transitioning to stage 3 T1D: experience from the GPPAD consortium
  R. Besser et al

AVAnT1A Manuscript Proposals:

• Anti-viral action against Type 1 diabetes autoimmunity: the GPPAD-AVAnT1A study protocol
  A. G. Ziegler, S. Hummel et al